Dr. Ashley Froese on Retatrutide: Why It's the "King" of Fat Loss Peptides, Fact-Checked

In March 2026, physician and content creator Dr. Ashley Froese posted "Dr. Explains Why Retatrutide is KING of Fat Loss Peptides" on her channel This Is Not Covered. The video walks through the GLP-1 to tirzepatide to retatrutide progression, explains the triple-agonist mechanism, and covers side effects including muscle loss, heart rate changes, and allodynia.

This page fact-checks her key claims against published clinical trial data and peer-reviewed research. Dr. Froese includes a disclaimer that this is not personalized medical advice.

The GLP-1 to GIP Progression: Tirzepatide's Advantage

"GIP receptors in the brain antagonize or dampen the nausea signals"

1:35

Dr. Froese explains that tirzepatide combines GLP-1 and GIP receptor agonism, and that GIP dampens the nausea triggered by GLP-1 alone:

"Research suggests that GIP receptors in the brain antagonize or dampen the nausea signals triggered by pure GLP-1 agonism. Essentially, Tirzepatide hits that stop eating button while simultaneously pushing a don't throw up button."

— Dr. Ashley Froese

Her explanation of the GLP-1 to tirzepatide progression is well-supported. The characterization of GIP as "doing most of the heavy lifting" is a simplification — both receptors contribute — but the overall framework is sound.

For more on these comparisons, see Retatrutide vs Mounjaro (Tirzepatide).

GIP and Futile Calcium Cycling

"A futile calcium cycle — revving your engine while in neutral"

2:15

Dr. Froese describes a mechanism by which GIP increases energy expenditure:

"Hitting your GIP receptors using tirzepatide causes a transient increase in energy expenditure for no good reason at all. We call it a futile calcium cycle, meaning a calcium pump in your cells gets activated and starts moving calcium back and forth across the membranes for no functional reason other than just to consume energy. It's like revving your engine while you're in neutral."

— Dr. Ashley Froese

This is one of the more impressive parts of the video. The futile calcium cycling mechanism is real and was published in Cell Metabolism in January 2025 — a relatively recent finding that many creators skip. Her analogy of "revving your engine in neutral" is apt. The minor error is attributing the oxygen consumption effect specifically to brown fat, when the published data points primarily to white adipocytes.

Retatrutide's Glucagon Component: The Metabolic "Cheat Code"

"Glucagon does this through mitochondrial uncoupling"

3:25

Dr. Froese argues that retatrutide's glucagon receptor agonism provides a metabolic advantage through thermogenesis:

"Glucagon does this through a process called mitochondrial uncoupling, essentially leaking protons through the electron transport chain... instead of making ATP, you get energy released purely as heat. The body literally starts wasting calories as heat."

— Dr. Ashley Froese

The biochemistry is correct. Glucagon receptor agonism does promote lipolysis and can drive mitochondrial uncoupling in adipose tissue. Where she slightly oversells it is the "exercise in a bottle" framing — she does qualify it with "obviously, it can't replace actual exercise," but the comparison still overstates what glucagon-mediated thermogenesis delivers. A 2026 multi-omic study confirmed retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming in mice (Diabetology & Metabolic Syndrome, April 2026).

For more on how retatrutide works, see What Is Retatrutide?.

Muscle Loss: "Up to 40% of Weight Lost Can Be Lean Mass"

"Up to 40% of weight lost can be lean mass"

5:05

Dr. Froese raises the muscle loss concern:

"What we've seen in the clinical trials so far is that up to 40% of weight lost on these GLP agonist peptide blends can be lean mass or muscle. 40%. That is 40% of your metabolic capacity."

— Dr. Ashley Froese

The 40% figure is at the upper end of the published range but is not wrong. However, conflating "lean mass" with "muscle" is a common oversimplification. Lean mass includes water, glycogen, and other non-muscle tissues. The SEMALEAN study (2025) found that despite lean mass decline, handgrip strength actually improved on semaglutide, suggesting functional muscle is better preserved than the raw lean mass numbers suggest.

For the full body composition analysis, see Retatrutide and Muscle Loss.

Heart Rate Increase: 5 to 10 BPM

"An increase of 5 to 10 beats per minute in resting heart rate"

6:55

"There's a natural pacemaker in your heart that has glucagon receptors on it. And so research is showing an increase of 5 to 10 beats per minute in resting heart rates."

— Dr. Ashley Froese

Her heart rate claim aligns with Phase 2 data. The mechanistic explanation attributing it to glucagon receptors on the sinoatrial node is reasonable, though GLP-1 receptor activation also affects heart rate. Worth noting that heart rate increases peaked at 24 weeks and then declined — a nuance she doesn't mention.

For related safety data, see Retatrutide Side Effects.

Allodynia at High Doses

"About 20% reported allodynia where their skin felt sunburned"

7:20

"About 20% of the participants in the studies on high doses — meaning 12 milligrams of retatrutide — reported a side effect of allodynia where their skin felt like it had been sunburned."

— Dr. Ashley Froese

This is one of the strongest fact-check sections. The 20% figure almost exactly matches the TRIUMPH-4 data (20.9% at 12mg). She correctly identifies this as a retatrutide-specific finding linked to the glucagon component, and the sensory neuron hypothesis is the current leading theory. Notably, the clinical term is "dysesthesia" rather than "allodynia" — she uses the more accessible term.

Pancreatitis Risk: "Less Than 0.5%"

"The risk for pancreatitis still exists but in the clinical trials the incidence was less than 0.5%."

— Dr. Ashley Froese

No confirmed pancreatitis was reported in Phase 2 trials. The less-than-0.5% figure likely draws from the broader GLP-1 agonist class data rather than retatrutide-specific trials. Regardless, it's a reasonable estimate and an appropriate caution to raise.

Dosing: The Trial Protocol

"The doses were 2 mg, 4 milligrams, 6, 9, and 12 milligrams spaced out in 4 week intervals."

— Dr. Ashley Froese

She slightly misstates the doses. The Phase 2 trial tested 1mg, 4mg, 8mg, and 12mg. The Phase 3 titration schedule uses 2mg, 4mg, 8mg, and 12mg — there were no 6mg or 9mg dose arms, though 9mg was used in TRIUMPH-4 alongside 12mg. The 4-week interval between dose increases is correct.

For the full dosing guide, see Retatrutide Dosage.

Microdosing and Receptor Desensitization

"You might actually accelerate tolerance"

9:00

"By microdosing and keeping those receptors under 24/7 high-level tension, you might actually accelerate tolerance, meaning you'd need higher and higher doses sooner to get the same effect."

— Dr. Ashley Froese

This is a theoretical claim she explicitly labels as such ("this is not fact, it's just a theory I have"). The underlying biology — that incretin receptors undergo desensitization and internalization when continuously stimulated — is well-established. Whether splitting a weekly dose into smaller daily doses meaningfully accelerates this process in practice is unknown. Her intellectual honesty in labeling this as speculation is appreciated.

For more on sub-clinical dosing, see Microdosing Retatrutide.

Frequently Asked Questions

Sources

• Froese, A. (2026). "Dr. Explains Why Retatrutide is KING of Fat Loss Peptides." This Is Not Covered (YouTube). Watch on YouTube
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Yu, M., et al. (2025). The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure. Cell Metabolism, 37:1-18. DOI: 10.1016/j.cmet.2024.11.003
• Douros, J.D. & Flak, J.N. (2025). GIP receptor agonism and GI tolerability of incretin-based therapies. Frontiers in Endocrinology. DOI: 10.3389/fendo.2025.1530985
• Eli Lilly (2025). TRIUMPH-4 Phase 3 results press release.
• SEMALEAN study (2025). Body composition outcomes with semaglutide 2.4mg. PMID: 41068996.

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

Dr. Ashley Froese's video is educational content and is not personalized medical advice. While she is a physician, she explicitly states she is not providing a doctor-patient relationship through her videos. Her explanations are generally well-supported by published data, with minor inaccuracies noted above.

Do not use this information to make decisions about your health without consulting a qualified healthcare provider. Do not purchase or self-administer grey market peptides based on YouTube videos or any information on this site.

This site is not affiliated with Dr. Ashley Froese, Eli Lilly and Company, or any pharmaceutical manufacturer.